1. GPCR/G Protein
  2. LPL Receptor

LPL Receptor

LPL Receptor (Lysophospholipid Receptor) group are members of the G protein-coupled receptor family of integral membrane proteins that are important for lipid signaling. In humans, there are eight LPL receptors, each encoded by a separate gene. These LPL receptor genes are also sometimes referred to as "Edg". LPL receptor ligands bind to and activate their cognate receptors located in the cell membrane. Depending on which ligand, receptor, and cell type is involved, the activated receptor can have a range of effects on the cell. These include primary effects of inhibition of adenylyl cyclase and release of calcium from the endoplasmic reticulum, as well as secondary effects of preventingapoptosis and increasing cell proliferation. Type: LPAR1, LPAR2, LPAR3, LPAR4, LPAR5, LPAR6, S1PR1, S1PR2, S1PR3, S1PR4, S1PR5.

LPL Receptor Related Products (21):

Cat. No. Product Name Effect Purity
  • HY-12355
    Siponimod Agonist 98.61%
    Siponimod(BAF-312) is a potent and selective S1P1 receptor agonist with EC50 of 0.4 nM; >10,000 fold potency for S1P3.
  • HY-15277
    AM966 Antagonist 98.75%
    AM966 is a high affinity, selective, oral LPA1-antagonist, inhibits LPA-stimulated intracellular calcium release (IC50=17 nM).
  • HY-13285
    Ki16425 Antagonist
    Ki16425 is a competitive, potent and reversible antagonist to LPA1, LPA2 and LPA3 with Ki of 0.34 μM, 6.5 μM and 0.93 μM, respectively, shows no activity at LPA4, LPA5, LPA6.
  • HY-12288
    Ozanimod Agonist 99.66%
    Ozanimod is a potent and selective S1P1 and S1P5 receptor agonist with EC50s of 410±160 pM and 11±4.3 nM in [35S]-GTPγS binding, respectively.
  • HY-16040
    AM095 free acid Inhibitor 99.28%
    AM095 (free acid) is a potent LPA1 receptor antagonist with IC50 values of 0.98 and 0.73 μM for recombinant human or mouse LPA1 respectively.
  • HY-100185
    Edg-2 receptor inhibitor 1
    Edg-2 receptor inhibitor 1 is an Edg-2 receptor inhibitor extracted from patent WO2009135590A1, Compound Example 14, has an IC50 of <0.1 μM.
  • HY-16039
    AM095 Antagonist 98.09%
    AM095 is a selective LPA1 receptor antagonist. The IC50 for AM095 antagonism of LPA-induced calcium flux of human or mouse LPA1-transfected CHO cells is 0.025 and 0.023 μM, respectively.
  • HY-18075
    LPA2 antagonist 1 Inhibitor 98.85%
    LPA2 antagonist 1 is a LPA2 antagonist with an IC50 of 17 nM.
  • HY-100619
    BMS-986020 Antagonist 98.02%
    BMS-986020 is an LPA1 antagonist.
  • HY-12789
    Etrasimod Antagonist 99.64%
    Etrasimod (APD334) is a potent, selective and orally available antagonist of the sphingosine-1-phosphate-1 (S1P1) receptor with an IC50 value of 1.88 nM in CHO cells.
  • HY-19736
    TY-52156 Antagonist 99.68%
    TY-52156 is a potent S1P3 receptor antagonist in a competitive manner, and the Ki value is estimated to be 110 nM for S1P3 receptor.
  • HY-10569
    Ponesimod Agonist 99.53%
    Ponesimod(ACT-128800) is an orally active, selective sphingosine-1-phosphate receptor 1 (S1P1) immunomodulator.
  • HY-17606
    Cenerimod Agonist 98.43%
    Cenerimod (ACT-334441) is a potent and orally available sphingosine 1-phosphate 1 receptor (S1P1) agonist extracted from patent WO 2016184939 A1 and WO 2011007324 A1, example 1, with an EC50 of 2.7 nM.
  • HY-16734A
    Amiselimod hydrochloride Agonist 98.91%
    Amiselimod hydrochloride is a novel sphingosine 1-phosphate receptor-1 (S1P1) modulator, designed to reduce the bradycardia effects associated with fingolimod and other S1P receptor modulators.
  • HY-100882
    ONO-7300243 Antagonist 98.04%
    ONO-7300243 is a novel, potent lysophosphatidic acid receptor 1 (LPA1) antagonist with IC50 of 0.16 μM.
  • HY-101265
    S1p receptor agonist 1 Agonist 98.28%
    S1p receptor agonist 1 is an S1P receptor agonist extracted from patent WO 2015039587 A1, compound example 2.
  • HY-104069
    AKP-11 Agonist 98.23%
    AKP-11 is a S1P1 agonist with immunomodulatory activities.
  • HY-13447A
    PF429242 dihydrochloride Inhibitor 98.76%
    PF429242 dihydrochloride is a reversible and competitive S1P inhibitor with an IC50 of 175 nM.
  • HY-12835
    S1P1 Agonist III Agonist 98.46%
    S1P1 Agonist III is a potent and orally active S1P1 agonist with EC50 of 18 nM; no activity on S1P3.
  • HY-101419
    CYM-5541 Agonist >98.0%
    CYM-5541 (ML249) is an selective and allosteric S1P3 receptor agonist with an EC50 between 72 and 132 nM.